Bolt Biotherapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-33.4M | $-63.1M | $-69.2M | $-88.1M | $-98.6M | $-60.7M |
| Depreciation & Amortization | $1.3M | $1.8M | $1.9M | $1.7M | $1.2M | $611.0K |
| Depreciation | $1.3M | $1.8M | $1.9M | $1.7M | $1.2M | $600.0K |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $2.8M | $7.4M | $9.2M | $9.6M | $8.5M | $1.4M |
| Net Cash from Operating Activities | $-39.9M | $-61.3M | $-69.5M | $-76.5M | $-57.1M | $-47.3M |
| Investing Activities | ||||||
| Capital Expenditures | $72.0K | $41.0K | $206.0K | $2.0M | $2.3M | $3.3M |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $44.3M | $57.6M | $71.0M | $57.9M | $-232.2M | $-20.6M |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $19.0K | $108.0K | $253.0K | $503.0K | $311.1M | $39.6M |
| Net Change in Cash | $4.5M | $-3.6M | $1.8M | $-18.1M | $21.8M | $-28.3M |
| Free Cash Flow | $-39.9M | $-61.3M | $-69.7M | $-78.5M | $-59.4M | $-50.6M |